Claudia Zacharias presents Gallium ⁶ PSMA-11 PET/MR Imaging in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer, a pilot study evaluating the detection rate for the initial diagnosis of prostate cancer and the metastatic spread for patients in the intermediate and high-risk prostate cancer risk category using ⁶⁸Ga-PSMA-11 PET/MR.  She reviews the potential role of ⁶⁸Ga-PSMA-11 PET/MR in primary prostate cancer and the hope to improve the localization of cancer within the prostate.

Biography:

Claudia Zacharias, MD, Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, California

Related Content:

Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer